• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

NPJ Vaccines . Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial

tetano

Editor, Senior Moderator
NPJ Vaccines


. 2021 Jul 14;6(1):89.
doi: 10.1038/s41541-021-00353-0.
Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial


Nadine G Rouphael[SUP] 1 [/SUP], Lilin Lai[SUP] 2 [/SUP], Sonia Tandon[SUP] 3 4 [/SUP], Michele Paine McCullough[SUP] 3 [/SUP], Yunchuan Kong[SUP] 4 [/SUP], Sarah Kabbani[SUP] 3 [/SUP], Muktha S Natrajan[SUP] 3 [/SUP], Yongxian Xu[SUP] 3 [/SUP], Yerun Zhu[SUP] 3 [/SUP], Dongli Wang[SUP] 3 [/SUP], Jesse O'Shea[SUP] 3 [/SUP], Amy Sherman[SUP] 3 [/SUP], Tianwei Yu[SUP] 4 [/SUP], Sebastien Henry[SUP] 5 [/SUP], Devin McAllister[SUP] 5 [/SUP], Daniel Stadlbauer[SUP] 6 [/SUP], Surender Khurana[SUP] 7 [/SUP], Hana Golding[SUP] 7 [/SUP], Florian Krammer[SUP] 6 [/SUP], Mark J Mulligan[SUP] 8 [/SUP], Mark R Prausnitz[SUP] 5 9 [/SUP]



Affiliations
Free article

Abstract

In a phase 1 randomized, single-center clinical trial, inactivated influenza virus vaccine delivered through dissolvable microneedle patches (MNPs) was found to be safe and immunogenic. Here, we compare the humoral and cellular immunologic responses in a subset of participants receiving influenza vaccination by MNP to the intramuscular (IM) route of administration. We collected serum, plasma, and peripheral blood mononuclear cells in 22 participants up to 180 days post-vaccination. Hemagglutination inhibition (HAI) titers and antibody avidity were similar after MNP and IM vaccination, even though MNP vaccination used a lower antigen dose. MNPs generated higher neuraminidase inhibition (NAI) titers for all three influenza virus vaccine strains tested and triggered a larger percentage of circulating T follicular helper cells (CD4 + CXCR5 + CXCR3 + ICOS + PD-1+) compared to the IM route. Our study indicates that inactivated influenza virus vaccination by MNP produces humoral and cellular immune response that are similar or greater than IM vaccination.
 
Back
Top Bottom